Amylin Loses Two Board Seats, but Won't Reincorporate in North Dakota
Biotech Amylin Pharmaceuticals lost two board seats today (May 27) in shareholder voting. Eastbourne Capital Management and corporate raider Carl Icahn, that have been waging a proxy fight against management, each won a seat. But the company won 10 seats on the 12-seat board. Both sides claimed victory. Icahn lost his proposal to reincorporate the company to North Dakota from Delaware. The dissidents claim that management has mishandled development of its diabetes drug Byetta, which it sells with Eli Lilly. The drug has been linked to cases of acute pancreatitis. Amylin stock rose 5.61% to $11.68.
More like this:
- Amylin Seeking Buyer — April 23, 2012
- Raider Icahn Says He Won Two Seats on Biotech Board — June 3, 2009
- Icahn, Other Big Shareholders Want Amylin's Chairman Cook to Step Down — April 15, 2009
- North Dakota Relocation? Amylin, Biogen Idec Shivering at Prospect — Feb. 20, 2009
- Three-Way Battle for Control of Biotech Amylin Looks Possible — Feb. 2, 2009